StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3025% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Devicor Medical / Mammotome by Quarter

Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — FDA 510(k) Clearances

QuarterlyAnnualMonthly

Danaher Devicor Medical / Mammotome: 0 in Q3 2026. That is the lowest of the 39 quarters on record here.

Latest, Q3 2026
0
Period ended Sep 30, 2026
Change on a year earlier
–
0 in Q3 2025
History
39 quarters
Since Q1 2016
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)

Where the Q3 2026 figure comes from

Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Reported in U.S. FDA openFDA Device 510(k) Clearances API.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDevicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — FDA 510(k) ClearancesYear on yearSource
Q3 2026Sep 30, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2026Jun 30, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2026Mar 31, 20262–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2025Dec 31, 20250-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2025Sep 30, 20250-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2025Jun 30, 20250–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2025Mar 31, 20250-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2024Dec 31, 20241–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2024Sep 30, 202410.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2024Jun 30, 20240–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2024Mar 31, 20241–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2023Dec 31, 20230–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2023Sep 30, 20231–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2023Jun 30, 20230-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2023Mar 31, 20230–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2022Dec 31, 20220–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Cite this data

StockData. (2026). Danaher Devicor Medical / Mammotome, quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-510k-mammotome-devicor

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.